Gowri Satyanarayana, MD
Infectious Disease · Atlanta, GANPI 1942493291
Payments from drug & device makers
Across 433 payments — averaging $925.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$393K
- Incyte Corporation$5K
- Astellas Pharma US Inc$593
- Takeda Pharmaceuticals U.S.A., Inc.$455
- AbbVie$432
- Paratek Pharmaceuticals, Inc.$196
- plus $2K from 26 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 299 | $392,563 |
| Incyte Corporation | 22 | $4,905 |
| Astellas Pharma US Inc | 17 | $593 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $455 |
| AbbVie | 21 | $432 |
| Paratek Pharmaceuticals, Inc. | 8 | $196 |
| Jazz Pharmaceuticals Inc. | 4 | $173 |
| Servier Pharmaceuticals LLC | 2 | $129 |
| Janssen Scientific Affairs, LLC | 1 | $122 |
| Ferring Pharmaceuticals Inc. | 4 | $118 |
| E.r. Squibb & Sons, L.L.C. | 1 | $116 |
| La Jolla Pharmaceutical Company | 4 | $92 |
| Johnson & Johnson | 5 | $92 |
| Sanofi-aventis U.S. LLC | 4 | $88 |
| Karyopharm Therapeutics Inc. | 5 | $85 |
| Insmed, Inc. | 4 | $81 |
| Gilead | 1 | $74 |
| Bristol Myers Squibb | 2 | $59 |
| Sobi, Inc | 3 | $48 |
| Genentech USA, Inc. | 2 | $47 |
| Shionogi Inc | 2 | $39 |
| Seagen Inc. | 2 | $38 |
| Acrotech Biopharma Inc. | 2 | $32 |
| Blueprint Medicines Corporation | 1 | $27 |
| Melinta Therapeutics, LLC | 1 | $26 |
| Rigel Pharmaceuticals, Inc. | 1 | $25 |
| AstraZeneca | 1 | $24 |
| Beigene USA, Inc. | 1 | $22 |
| Sanofi | 1 | $20 |
| Stemline Therapeutics Inc. | 1 | $20 |
| Amgen | 1 | $14 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $14 |
How this compares
$400,769 in reported general payments places this provider in the 90th percentile of 260 infectious disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other infectious disease in Atlanta
- Mark MulliganAtlanta$4.6M
- Nadine RouphaelAtlanta$2.4M
- Leila HojatAtlanta$2.2M
- Kimberly WorkowskiAtlanta$2M
- Zandraetta Tims-CookAtlanta$878K
- Scott FridkinAtlanta$774K
- Colleen KelleyAtlanta$738K
- Leandro MenaAtlanta$733K
- Srilatha EdupugantiAtlanta$726K
- Larry AndersonAtlanta$694K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.